...
首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Catechin-loaded Eudragit microparticles for the management of diabetes: formulation, characterization and in vivo evaluation of antidiabetic efficacy
【24h】

Catechin-loaded Eudragit microparticles for the management of diabetes: formulation, characterization and in vivo evaluation of antidiabetic efficacy

机译:加载CaeteChin的Eudragit微粒用于糖尿病的管理:制剂,表征和体内抗糖尿病疗效评估

获取原文
获取原文并翻译 | 示例
           

摘要

Catechin (CT) is natural molecule proved for antidiabetic activity. Clinical application of CT is highly restricted because of its low bioavailability and ineffectiveness in in vivo conditions. Therefore, the main objective of the present investigation was to formulate CT-loaded Eudragit RS 100 microparticles and evaluated for its potential against diabetes. CT microparticles showing highest entrapment efficiency of 92.3 +/- 6.5% and higher percentage yield of 63.46 +/- 4.3% was selected as optimised formulation. CT microparticles treated rats showed significantly lower blood glucose, cholesterol, LDL, free fatty acid and triglyceride concentrations in comparison to pristine CT-treated rats. The glucose and lipid profiles of microparticle formulation were akin to normal rats. Moreover, CT microparticles did not produce obesity even after 60 days which is a comment side effect of antidiabetic drugs. These results indicate that the CT microparticles can be applied as potential and safe carrier for the treatment of diabetes.
机译:儿茶素(CT)是用于抗糖尿病活性的天然分子。 CT的临床应用受到高度限制,因为其在体内病症的低生物利用度和无效性。因此,本研究的主要目的是配制CT加载的Eudragit 100微粒,并评估其对糖尿病的潜力。 CT微粒显示出最高的夹带效率为92.3 +/- 6.5%,较高百分比的产量为63.46 +/- 4.3%的优化配方。与原始CT处理的大鼠相比,CT微粒治疗的大鼠显着降低血糖,胆固醇,LDL,游离脂肪酸和甘油三酯浓度。微粒制剂的葡萄糖和脂质谱类似于正常大鼠。此外,即使在60天后,CT微粒也不会产生肥胖,这是抗糖尿病药物的评论副作用。这些结果表明,CT微粒可以应用于用于治疗糖尿病的潜在和安全载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号